References

  1. Palella Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine. 1998; 338(13): 853-60. PubMed | Google Scholar

  2. UNAIDS. How AIDS changed everything. Accessed on 26 November 2016.

  3. UNAIDS. The HIV and AIDS Uganda Country Progress Report 2014. Accessed on 6 October 2015.

  4. Uganda AIDS Commission. HIV and AIDS Uganda Country Progress Report 2013. Accessed on 6 October 2015.

  5. Hogg RS, Yip B, Kully C, Craib KJ, O'shaughnessy MV, Schechter MT. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. Canadian Medical Association Journal. 1999; 160(5): 659-65. PubMed | Google Scholar

  6. Hirschel B, Opravil M. The year in review: antiretroviral treatment. AIDS (London, England). 1999; 13 Suppl A: S177-87. PubMed | Google Scholar

  7. Notermans DW, Jurriaans S, de Wolf F, Foudraine NA, de Jong JJ, Cavert W. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Aids. 1998; 12(2): 167-73. PubMed | Google Scholar

  8. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine. 1997; 337(11): 734-9. PubMed | Google Scholar

  9. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Annals of internal Medicine. 2002 Sep 3; 137(5 Pt 2): 381-433. PubMed | Google Scholar

  10. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society?USA Panel. Jama. 2000; 283(3): 381-90. PubMed | Google Scholar

  11. Flexner C. HIV-protease inhibitors. New England Journal of Medicine. 1998; 338(18): 1281-93. PubMed | Google Scholar

  12. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral therapy. 2000; 5(1): 41-8. PubMed | Google Scholar

  13. Ministry of Health Uganda. Addendum to the National Antiretroviral Treatment Guidelines for Uganda. 2013. Accessed on 3 February 2017.

  14. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. New England Journal of Medicine. 1996; 335(15): 1091-8. PubMed | Google Scholar

  15. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Archives of internal medicine. 2003; 163(18): 2187-95. PubMed | Google Scholar

  16. Moore RD, Keruly JC, Gebo KA, Lucas GM. An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2005; 39(2): 195-8. PubMed | Google Scholar

  17. Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. Aids. 1999; 13(14): 1873-80. PubMed | Google Scholar

  18. Mellors JW, Rinaldo Jr CR, Gupta P, White RM. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996; 272(5265): 1167. PubMed | Google Scholar

  19. O'brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. New England Journal of Medicine. 1996; 334(7): 426-31. PubMed | Google Scholar

  20. Piacenti FJ. An update and review of antiretroviral therapy. Pharmacotherapy: the Journal of Human Pharmacology and Drug Therapy. 2006; 26(8): 1111-33. PubMed | Google Scholar

  21. Deeks SG. Determinants of virological response to antiretroviral therapy: implications for long-term strategies. Clinical Infectious Diseases. 2000; 30(Supplement 2): S177-S84. PubMed | Google Scholar

  22. Keiser O, Tweya H, Boulle A, Braitstein P, Schechter M, Brinkhof MW et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS (London, England). 2009; 23(14): 1867. PubMed | Google Scholar

  23. Llibre JM, Cardona G, Santos JR, Andreu A, Estrada JO, Ara J et al. Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain. Clinicoecon Outcomes Res. 2013; 5: 215-21. PubMed | Google Scholar

  24. Morgan D, Malamba SS, Maude GH, Okongo MJ, Wagner H-U, Mulder DW. An HIV-1 natural history cohort and survival times in rural Uganda. Aids. 1997; 11(5): 633-40. PubMed | Google Scholar

  25. Ministry of Health Uganda. National Antiretroviral Treatment and Care Guidelines for Adults and Children First Edition 2003. Accessed on February 3 2017.

  26. Ministry of Health Uganda. Uganda Clinical Guidelines 2003-National Guidelines on Management of Common Conditions, First Edition 2003. Accessed on February 3 2017.

  27. Victora CG, Huttly SR, Fuchs SC, Olinto M. The role of conceptual frameworks in epidemiological analysis: a hierarchical approach. International journal of epidemiology. 1997; 26(1): 224-7. PubMed | Google Scholar

  28. El-Khatib Z, Katzenstein D, Marrone G, Laher F, Mohapi L, Petzold M. Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One. 2011; 6(3): e17518. PubMed | Google Scholar

  29. Pujades-Rodriguez M, O'brien D, Humblet P, Calmy A. Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres. AIDS. 2008; 22(11): 1305-12. PubMed | Google Scholar

  30. Kawuma R, Bernays S, Siu G, Rhodes T, Seeley J. "Children will always be children": exploring perceptions and experiences of HIV-positive children who may not take their treatment and why they may not tell. African Journal of AIDS Research. 2014; 13(2): 189-95. PubMed | Google Scholar

  31. Charurat M, Oyegunle M, Benjamin R, Habib A, Eze E, Ele P. Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS One. 2010; 5(5): e10584. PubMed | Google Scholar

  32. Petersen ML, Tran L, Geng EH, Reynolds SJ, Kambugu A, Wood R. Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa. AIDS (London, England). 2014; 28(14): 2097. PubMed | Google Scholar

  33. Kalichman SC, Grebler T, Amaral CM, McNerey M, White D, Kalichman MO. Intentional non-adherence to medications among HIV positive alcohol drinkers: prospective study of interactive toxicity beliefs. Journal of general internal medicine. 2013; 28(3): 399-405. PubMed | Google Scholar

  34. Kalichman SC, Grebler T, Amaral CM, McNerney M, White D, Kalichman MO et al. Viral suppression and antiretroviral medication adherence among alcohol using HIV-positive adults. International journal of behavioral medicine. 2014; 21(5): 811-20. PubMed | Google Scholar

  35. Kekwaletswe CT, Morojele NK. Alcohol use, antiretroviral therapy adherence and preferences regarding an alcohol-focused adherence intervention in patients with human immunodeficiency virus. Patient Preference & Adherence. 2014 Mar 31; 8: 401-13. PubMed | Google Scholar

  36. Idindili B, Jullu B, Mugusi F, Tanner M. A case-control study of factors associated with non-adherence to antiretroviral therapy among HIV infected people in Pwani Region, Eastern Tanzania. Tanzania journal of health research. 2012 Jul; 14(3): 194-203. PubMed | Google Scholar

  37. Meriki HD, Tufon KA, Afegenwi MH, Nyindem BA, Atanga PN, Anong DN. Immuno-haematologic and virologic responses and predictors of virologic failure in HIV-1 infected adults on first-line antiretroviral therapy in Cameroon. Infectious Diseases of Poverty. 2014; 3(1): 5. PubMed | Google Scholar

  38. Ogoina D, Obiako RO, Muktar HM, Adeiza M, Babadoko A, Hassan A et al. Morbidity and mortality patterns of hospitalised adult HIV/AIDS patients in the era of highly active antiretroviral therapy: a 4-year retrospective review from Zaria, Northern Nigeria. AIDS research and treatment. 2012; 2012: 940580. PubMed | Google Scholar